Prolor has received two new patents, 7553940 and 7553941, from the US Patent and Trademark Office (PTO), for its long-acting CTP-enhanced human growthhormone (hGH-CTP) and human erythropoietin (EPO-CTP).
Prolor’s CTP technology is based on a short amino acid sequence, the Carboxyl Terminal Peptide that occurs naturally in humans. When attached to a therapeutic protein, CTP extends the time that the protein is active in the body.
Prolor now plans to initiate human clinical trials with hGH-CTP, its longer-acting version of human growth hormone, later this year.
Shai Novik, President, Prolor, said: These two new patents covering CTP-enhanced human growth hormone and erythropoietin represent another significant layer of protection within our CTP-based intellectual property portfolio.
We have also filed several other patent applications for additional CTP-enhanced long-acting therapeutic proteins and peptides that are currently pending. We are confident that our growing CTP patent estate will provide excellent protection for both our compounds under development and for our innovative and versatile platform technology, and we believe it will serve as an important value driver for Prolor in the future, he added.